Circulating tumor DNA analysis from the Evidence trial
Release date:
2025-12-01
Description:
The EVIDENCE was a phase 3, multicenter, randomized, open-label trial conducted in China (NCT02448797). This post-hoc minimal residual disease (MRD) analysis of the EVIDENCE study aimed to evaluate the prognostic and monitoring utility of ctDNA-based MRD in early-stage, resected EGFR-mutated NSCLC patients receiving adjuvant therapy.
For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.
You need to install the Aspera Connect plugin before uploading your files. If you dont have Aspera Connect plugin installed in your computer, please Download Aspera Connectand install it first.
[path/to/ascp]: Microsoft Windows: C:\Program Files\Aspera\Aspera Connect\bin\ascp.exe or
c:\users\[username]\AppData\Local\Programs\Aspera\Aspera Connect\bin\ascp.exe
Mac OS X: /Applications/Aspera/Connect.app/Contents/Resources/ascp (for admin's installation) or
/Users/[username]/Applications/Aspera/Connect.app/Contents/Resources/ascp (for non-admin's installation)
Linux: /opt/aspera/bin/ascp or
/home/[username]/aspera/connect/bin/ascp
[path/to/key/file] must be an absolute path, e.g.: /home/keys/aspera.openssh
[path/to/folder/containing/files] needs to specify the local folder that contains all the files to upload.
HRA010674.xlsx